Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGLC NASDAQ:BRTX NYSE:CCM NASDAQ:MRAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGLCBioNexus Gene Lab$5.10-23.1%$3.87$2.01▼$15.60$11.91M5.08532,432 shs352,831 shsBRTXBiorestorative Therapies$1.57-1.3%$1.68$1.21▼$2.55$11.78M75.28145,123 shs84,308 shsCCMConcord Medical Services$5.29-2.0%$6.59$3.80▼$10.50$23.45M-0.916,223 shs544 shsMRAIMarpai$1.28-6.6%$1.33$0.40▼$1.68$21.17M4.6817,380 shs16,687 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGLCBioNexus Gene Lab-23.08%+0.20%+74.06%+86.81%-3.77%BRTXBiorestorative Therapies-1.26%-3.09%-7.65%-10.29%-6.55%CCMConcord Medical Services-5.11%-5.52%-9.09%+26.13%-37.54%MRAIMarpai-6.57%-8.57%+2.40%+21.90%+88.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGLCBioNexus Gene Lab0.4514 of 5 stars0.05.00.00.01.10.00.0BRTXBiorestorative Therapies3.5367 of 5 stars3.55.00.00.01.83.30.6CCMConcord Medical Services0.8489 of 5 stars0.05.00.00.00.01.70.6MRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGLCBioNexus Gene Lab 0.00N/AN/AN/ABRTXBiorestorative Therapies 3.00Buy$18.001,046.50% UpsideCCMConcord Medical Services 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGLCBioNexus Gene Lab$9.51M0.97N/AN/A$4.63 per share1.10BRTXBiorestorative Therapies$391K30.14N/AN/A$1.23 per share1.28CCMConcord Medical Services$383.96M0.06N/AN/A$51.05 per share0.10MRAIMarpai$34.87M0.61N/AN/A($1.72) per share-0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGLCBioNexus Gene Lab-$1.60MN/A0.00∞N/A-22.85%-24.18%-20.14%N/ABRTXBiorestorative Therapies-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)CCMConcord Medical Services-$42.23MN/A0.00∞N/AN/AN/AN/AN/AMRAIMarpai-$28.75M-$1.82N/A∞N/A-85.70%N/A-100.23%8/5/2025 (Estimated)Latest BGLC, CCM, MRAI, and BRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BRTXBiorestorative Therapies-$0.41N/AN/AN/A$0.34 millionN/A5/15/2025Q1 2025BGLCBioNexus Gene LabN/A-$0.03N/A-$0.03N/AN/A5/14/2025Q1 2025BRTXBiorestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGLCBioNexus Gene LabN/AN/AN/AN/AN/ABRTXBiorestorative TherapiesN/AN/AN/AN/AN/ACCMConcord Medical ServicesN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGLCBioNexus Gene LabN/A4.193.44BRTXBiorestorative TherapiesN/A2.242.24CCMConcord Medical Services1.670.460.45MRAIMarpaiN/A0.820.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGLCBioNexus Gene Lab18.85%BRTXBiorestorative Therapies69.38%CCMConcord Medical ServicesN/AMRAIMarpai49.75%Insider OwnershipCompanyInsider OwnershipBGLCBioNexus Gene Lab0.70%BRTXBiorestorative Therapies25.50%CCMConcord Medical Services46.50%MRAIMarpai46.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGLCBioNexus Gene Lab301.80 million1.78 millionNot OptionableBRTXBiorestorative Therapies77.51 million5.59 millionNot OptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableMRAIMarpai15016.54 million5.61 millionNo DataBGLC, CCM, MRAI, and BRTX HeadlinesRecent News About These CompaniesEarnings call transcript: Marpai posts improved Q1 2025 results amid cost cutsMay 17, 2025 | uk.investing.comMarpai, Inc. Reports Q1 2025 Financial ResultsMay 15, 2025 | tipranks.comMarpai targets cash flow positivity in 2025 with cost reductions and leadership changesMay 15, 2025 | msn.comMarpai, Inc. (MRAI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comMarpai appoints new COO to accelerate growthMay 15, 2025 | uk.investing.comMARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSMay 14, 2025 | prnewswire.comMARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICERMay 13, 2025 | prnewswire.comMarket Access RICI Agriculture UCITS (MRAI)May 8, 2025 | investing.comMARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTSMay 7, 2025 | prnewswire.comMarpai, Inc. to Present at the Planet MicroCap Showcase Las VegasApril 15, 2025 | prnewswire.comMarpai targets profitability in 2025 with new initiatives and strategic partnershipsMarch 27, 2025 | msn.comMarpai, Inc. (MRAI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comMARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSMarch 26, 2025 | prnewswire.comMARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSMarch 20, 2025 | prnewswire.comMARPAI ACCELERATES HEALTHCARE TRANSFORMATION WITH EMPARA COLLABORATION, LAUNCHING UNIFIED HEALTH ENGAGEMENT PLATFORMMarch 18, 2025 | prnewswire.comHealth In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded SolutionsJanuary 22, 2025 | prnewswire.comMARPAI ANNOUNCES SECOND TRANCHE OF NON-DILUTIVE GROWTH FUNDING WITH UP TO $5 MILLION FROM JGBJanuary 6, 2025 | prnewswire.comMARPAI ANNOUNCES PRICING OF $700,000 PRIVATE PLACEMENTDecember 5, 2024 | prnewswire.comMARPAI ANNOUNCES GENERAL UPDATES FOR Q4November 26, 2024 | prnewswire.comMarpai, Inc. Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBGLC, CCM, MRAI, and BRTX Company DescriptionsBioNexus Gene Lab NASDAQ:BGLC$5.10 -1.53 (-23.08%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.69 -0.41 (-8.06%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.Biorestorative Therapies NASDAQ:BRTX$1.57 -0.02 (-1.26%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.60 +0.03 (+1.91%) As of 07/18/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Concord Medical Services NYSE:CCM$5.29 -0.11 (-2.02%) Closing price 07/18/2025 03:58 PM EasternExtended Trading$5.24 -0.05 (-0.87%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.Marpai NASDAQ:MRAI$1.28 -0.09 (-6.57%) As of 07/18/2025 03:57 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
